Market closedNon-fractional
Ligand Pharmaceuticals/LGND
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ticker
LGND
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Jupiter, United States
Employees
58
Website
www.ligand.com
LGND Metrics
BasicAdvanced
$1.5B
Market cap
15.68
P/E ratio
$5.41
EPS
0.92
Beta
-
Dividend rate
Price and volume
Market cap
$1.5B
Beta
0.92
Financial strength
Current ratio
20.705
Quick ratio
19.173
Long term debt to equity
0.644
Total debt to equity
0.768
Interest coverage (TTM)
-2.51%
Management effectiveness
Return on assets (TTM)
-0.10%
Return on equity (TTM)
13.26%
Valuation
Price to earnings (TTM)
15.68
Price to revenue (TTM)
12.52
Price to book
1.88
Price to tangible book (TTM)
3.7
Price to free cash flow (TTM)
-88.35
Growth
Revenue change (TTM)
-41.92%
Earnings per share change (TTM)
285.65%
3-year revenue growth
-17.20%
3-year earnings per share growth
31.03%
What the Analysts think about LGND
Analyst Ratings
Majority rating from 5 analysts.
LGND Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$31M
9.96%
Net income
$86M
375.69%
Profit margin
278.64%
332.60%
LGND Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.42
$1.02
$1.38
$1.20
-
Expected
$0.64
$0.61
$0.66
$0.78
$0.99
Surprise
121.96%
67.21%
108.85%
54.00%
-
LGND News
AllArticlesVideos
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
Business Wire·2 weeks ago
Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ligand Pharmaceuticals stock?
Ligand Pharmaceuticals (LGND) has a market cap of $1.5B as of July 05, 2024.
What is the P/E ratio for Ligand Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ligand Pharmaceuticals (LGND) stock is 15.68 as of July 05, 2024.
Does Ligand Pharmaceuticals stock pay dividends?
No, Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Ligand Pharmaceuticals dividend payment date?
Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ligand Pharmaceuticals?
Ligand Pharmaceuticals (LGND) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Ligand Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.